SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

SAB Biotherapeutics, Inc.

SAB Bio develops disease-modifying therapies for people impacted by type 1 diabetes.

SAB Bio

A clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D)

National Institutes of Health

U.S. Department of Defense

JDRF T1D Fund

BVF Partners

Commodore Capital

Marshall Wace

RA Capital Management

RTW Investments

Sessa Capital

T. Denny Sanford

South Dakota Equity Partners

Merck

Sioux Falls Development Foundation

SAB BIO

We are excited to announce we have evolved our name and visual identity! 

This is an important milestone, reflecting our strategic evolution and focus on addressing serious unmet needs in #type1diabetes. We look forward to showcasing our new branding during our poster presentation at the American Diabetes Association  84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida and hope to see you there!

Read more about this announcement and check out our website at sab.bio.

#t1d #type1diabetes #diabetes #ADASciSessions

We are pleased to welcome @Lucy To as our newly appointed CFO, effective August 12. 

Lucy joins SAB with more than 18 years of investment banking and strategic operational expertise to SAB and will lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company.

Read more about her joining SAB in the release found here: https://lnkd.in/dkHPUyH2

SAB was featured in the latest publication of Refresh Miami - link below!

What an incredible week we've had attending American Diabetes Association #adascisessions and meeting reknowned #type1diabetes advocates, researchers and thought leaders. 

Attending SAB BIO representatives included our Chairman and CEO Samuel Reich, our Co-Founder and President Eddie J Sullivan, EVP and COO Christoph Bausch, VP of Clinical Operations Angela Parizek, VP of Clinical Development Stan Stoyanov MD, MBA, and Senior Program Manager Eric Sandhurst, PhD. 

We look forward to continuing to build relationships with the other attendees we met. See you next year!

We are pleased to note our upcoming poster presentation at this week's American Diabetes Association #scientificsessions in Orlando on Sunday, June 23 for #ADA2024. 

Details about where to find our poster and connect with the presenter can be found below. 

https://lnkd.in/eX58xMxh

We've met so many incredible #type1diabetes advocates during the American Diabetes Association #ADAscisessions, and today SAB Senior Program Manager Eric Sandhurst, PhD presented in the Poster Hall and took questions. Also pictured below is our COO & EVP, Christoph Bausch. 

We'll be here one more day in the Poster Hall at 885-P if you'd like to check out our presentation. Come say hello!

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	3.44M -	55.24M 1,504.91%	60.88M 10.21%	23.90M 60.73%	2.24M 90.63%
cost of revenue			1.65M -	3.29M 99.07%	3.75M 13.77%
gross profit	3.44M -	55.24M 1,504.91%	59.22M 7.21%	20.61M 65.20%	-1.51M 107.31%
selling and marketing expenses					-3.75M -
general and administrative expenses	4.10M -	6.77M 65.35%	17.09M 152.29%	16.38M 4.11%	23.80M 45.27%
selling general and administrative expenses	4.10M -	6.77M 65.35%	17.09M 152.29%	16.38M 4.11%	20.05M 22.41%
research and development expenses	8.02M -	27.91M 248.00%	57.18M 104.90%	36.44M 36.28%	16.52M 54.68%
other expenses	2.59K -	4.00K 54.05%	-60.88M 1,523,525.38%	-23.90M 60.73%
cost and expenses	12.12M -	34.68M 186.26%	13.39M 61.38%	28.92M 115.91%	40.31M 39.41%
operating expenses	12.12M -	34.68M 186.26%	13.39M 61.38%	28.92M 115.91%	36.57M 26.46%
interest expense	428.48K -	469.15K 9.49%	294.46K 37.24%	301.58K 2.42%	-315.28K 204.54%
ebitda	-8.23M -	21.14M 356.67%	-11.71M 155.41%	-27.16M 131.91%	-34.33M 26.40%
operating income	-8.67M -	20.56M 337.01%	-13.39M 165.15%	-28.92M 115.91%	-38.08M 31.67%
depreciation and amortization	439.13K -	578.30K 31.69%	1.68M 190.88%	1.76M 4.53%	3.75M 112.99%
total other income expenses net	-312.75K -	-439.02K 40.38%	-3.75M 754.47%	10.20M 371.97%	-4.12M 140.37%
income before tax	-8.99M -	20.12M 323.87%	-17.14M 185.22%	-18.72M 9.16%	-42.19M 125.45%
income tax expense	431.07K -	473.15K 9.76%	299.95K 36.61%	25.63K 91.46%	-2 100.01%
net income	-9.42M -	20.12M 313.62%	-17.44M 186.71%	-18.74M 7.43%	-42.19M 125.14%
weighted average shs out	43.47M -	2.54M 94.16%	2.73M 7.67%	4.35M 59.20%	5.52M 26.86%
weighted average shs out dil	43.47M -	2.70M 93.79%	2.73M 1.21%	4.35M 59.20%	5.52M 26.86%
eps	-0.22 -	7.92 3,700%	-6.38 180.56%	-4.31 32.45%	-7.64 77.26%
epsdiluted	-0.22 -	7.45 3,486.36%	-6.38 185.64%	-4.31 32.45%	-7.64 77.26%

BIO:SAB

SAB Bio

Last Close

4.13

05/11 21:00

Market Cap

29.53M

Beta: -

Volume Today

60.47K

Avg: -

Preview